Karachaliouet al. [44] showed interesting data of different expression of ROR1 in lung adenocarcinoma patients with EGFR mutations sensitive or insensitive to Erlotinib which indicated that ROR1 expression is more associated with EGFR mutation status and that ROR1-directed therapies can enhance the efficacy of Erlotinib therapy. The gene discussed is EGFR; the disease is lung adenocarcinoma.